Frequently Asked Questions
In 2022, the market for Small Scale Bioreactors was estimated to be worth USD 1745.8 million.
The market for small-scale bioreactors is anticipated to increase at a CAGR of 15.30% from 2023 to 2030, reaching USD 5452.91 million in 2030.
Single-use bioreactors are the most popular category of type of bioreactors.
Micro bioreactors, by the scale of operation, are the notable segment.
During the projection period, the cell culture category is anticipated to exhibit the highest CAGR.
The small-scale bioreactors market was ruled by North America.
The top players include Sartorius AG; Thermo Fisher Scientific Inc.; Merck KGaA; Danaher Corp.; Lonza Group; Eppendorf AG; Miltenyi Biotec; Getinge AB; Solaris Biotechnology Srl; Infors AG, and others.
The biopharmaceutical sector is rapidly moving towards the use of single-use bioprocessing systems with integrated real-time monitoring and technical analysis that can simplify automation, strengthen data-driven quality control, and keep driving performance due to the demand for better quality and greater efficiency in drug manufacturing.
The challenges limiting the growth of the small-scale bioreactors market are regulatory compliance, limited capacity, resource constraints, and environmental concerns.
Small-scale bioreactors are being utilized more frequently in the food and beverage industry to make fermented foods and beverages, including yogurt, cheese, and beer.